Transforming growth factor-beta signalling in brain disorders

Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):121-8. doi: 10.1016/j.cytogfr.2005.09.011. Epub 2005 Nov 3.

Abstract

Transforming growth factor-beta (TGF-beta) has been characterized as an injury-related factor, based on the observation that it is strongly up-regulated in many acute or chronic central nervous system disorders. TGF-beta is generally thought to be neuroprotective and several mechanisms have been proposed to explain this beneficial action. For instance, TGF-beta protects neurons against the potentiating effect of tissue-type plasminogen activator on NMDA receptor-mediated excitotoxicity, by up-regulating type-1 plasminogen activator inhibitor expression in astrocytes. TGF-beta has also anti-apoptotic properties, through a recruitment of a mitogen-activated protein kinase pathway and a concomitant activation of anti-apoptotic members of the Bcl-2 family. These multiple mechanisms might reflect the pleiotropic nature of TGF-beta, reinforcing the potential therapeutic value of this cytokine in several central nervous system disorders.

Publication types

  • Review

MeSH terms

  • Animals
  • Brain Diseases / drug therapy
  • Brain Diseases / metabolism*
  • Brain Diseases / pathology*
  • Disease Progression
  • Humans
  • Receptors, Transforming Growth Factor beta / physiology
  • Signal Transduction / physiology*
  • Transforming Growth Factor beta / physiology*

Substances

  • Receptors, Transforming Growth Factor beta
  • Transforming Growth Factor beta